Sort
23,748 grants matching “melanoma”
Melanoma RAS/BRAF Mutation: Heterogeneity-Risk-Prognosis
$479,355Nancy E Thomas · Univ Of North Carolina Chapel Hill · R01 · FY2014 · CA
B7-H1/PD-1 modulation in cancer therapy
$479,334Drew M. Pardoll · Johns Hopkins University · R01 · FY2011 · CA
Targeting Oncogene Expression to Skin in Transgenic Mice
$479,145Dennis Roop · University Of Colorado Denver · R01 · FY2012 · CA
Proton-coupled folate/antifolate transport
$479,143Israel David Goldman · Albert Einstein College Of Medicine · R01 · FY2013 · CA
Molecular Interactions during Neural Crest Formation
$479,083Martin Ignacio Garcia-Castro · University Of California Riverside · R01 · FY2024 · DE
Efficacy of Web-based Training in Skin Cancer Triage
$479,081Martin A. Weinstock · Rhode Island Hospital · R01 · FY2006 · CA
A Study of Telomeres in an Arsenic-Exposed Bangladesh Cohort
$479,012Brandon Lee Pierce · University Of Chicago · R01 · FY2012 · ES
The identification of genetic determinants of melanoma recurrence
$478,926Tomas Kirchhoff · New York University School Of Medicine · R01 · FY2015 · CA
Gasdermin E and pyroptosis in cancer
$478,863Judy Lieberman · Boston Children'S Hospital · R01 · FY2024 · CA
Cancer Center Support Grant
$478,830Harold E Varmus · Sloan-Kettering Inst Can Research · P30 · FY2009 · CA
Targeting innate immune pathways in breast cancers with chromosomal instability
$478,720Samuel F Bakhoum · Sloan-Kettering Inst Can Research · P50 · FY2020 · CA
Understanding and Overcoming Resistance to BRAF/MEK Kinase Inhibitors in Melanoma
$478,669Arjun Raj · University Of Pennsylvania · R01 · FY2024 · CA
Tumor Organoid-Mediated Drug Testing and Clonality Analysis in Peritoneal Surface Disease of Intestinal Origin
$478,598Konstantinos Votanopoulos · Wake Forest University Health Sciences · R01 · FY2024 · CA
Defining and targeting epigenetic plasticity-driven drug resistance and immune escape in melanoma
$478,486Keiran Smalley · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2023 · CA
Biology of Fungal Melanin
$478,446Arturo Casadevall · Albert Einstein College Of Medicine · R01 · FY2009 · AI
A Phase 1 Study of M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma.
$478,440James M Markert · University Of Alabama At Birmingham · R01 · FY2019 · CA
Uncovering the Origin and Growth Regulation of Melanocytic Nevi
$478,438Anand K Ganesan · University Of California-Irvine · R56 · FY2019 · AR
Targeting the MAP and PI3 Kinase Pathways in Melanoma
$478,396Meenhard Herlyn · Wistar Institute · P01 · FY2011 · CA
Melanoma: Metabolic Biomarkers of Response to Targeted Therapy
$478,396Jerry D Glickson · University Of Pennsylvania · R01 · FY2020 · CA
EASTERN COOPERATIVE ONCOLOGY GROUP
$478,386University Of Rochester · U10 · FY2000 · CA
Mechanisms of uveal melanoma dormancy and targeted therapy tolerance
$478,344Andrew E Aplin · Thomas Jefferson University · R01 · FY2021 · CA
Immune profiling of multi-parameter flow cytometry using computational statistics
$478,256Cliburn C Chan · Duke University · RC1 · FY2010 · AI
Molecular Mechanism and Therapy for Ocular Melanoma
$478,245Joan Heller Brown · University Of California, San Diego · R01 · FY2022 · CA
UNDERSTANDING THE PROGNOSTIC IMPACT OF NK CELL HETEROGENEITY IN MELANOMA. NEW AWARD.
$478,129The Leland Stanford Junior University · · FY2020 · Defense Health Agency
Senescence as a Therapeutic Endpoint
$478,108Meenhard Herlyn · Wistar Institute · P01 · FY2015 · CA